Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 16, 2009, Pages 2630-2637

  Baselga, José ^a   Semiglazov, Vladimir ^a   Van Dam, Peter ^a   Manikhas, Alexey ^a   Bellet, Meritxell ^a   Mayordomo, José ^a   Campone, Mario ^a   Kubista, Ernst ^a   Greil, Richard ^a   Bianchi, Giulia ^a   Steinseifer, Jutta ^a   Molloy, Betty ^a   Tokaji, Erika ^a   Gardner, Humphrey ^a   Phillips, Penny ^a   Stumm, Michael ^a   Lane, Heidi A ^a   Dixon, J Michael ^a   Jonat, Walter ^a   Rugo, Hope S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR; EVEROLIMUS; KI 67 ANTIGEN; LETROZOLE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; AROMATASE INHIBITOR; CCND1 PROTEIN, HUMAN; DRUG DERIVATIVE; NITRILE; PIK3CA PROTEIN, HUMAN; RAPAMYCIN; S6 KINASE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST BIOPSY; BREAST CANCER; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ERUPTION; DRUG POTENTIATION; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENTAL DISEASE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTMENOPAUSE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SLEEP DISORDER; STOMATITIS; THROMBOCYTOPENIA; ADJUVANT THERAPY; BIOPSY; BREAST TUMOR; CELL PROLIFERATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EUROPE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PALPATION; PATHOLOGY; PHOSPHORYLATION; TIME; TREATMENT OUTCOME; UNITED STATES;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BIOPSY; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CYCLIN D1; DOUBLE-BLIND METHOD; EUROPE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; NITRILES; PALPATION; PHOSPHORYLATION; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RIBOSOMAL PROTEIN S6 KINASES; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 66849136781     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.8391     Document Type: Article

References (30)

1. Shaw RJ, Cantley LC: Ras, PI(3)K and mTOR signalling controls tumor cell growth. Nature 441: 424-430, 2006
2. Tanaka C, O'Reilly T, Kovarik JM, et al: Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26:1596-1602, 2008
3. O'Reilly T, Vaxelaire J, Muller M, et al: In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 43:71, 2002 (abstr 359)
4. Ellard S, Gelmon KA, Chia S, et al: A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer. J Clin Oncol 25:141s, 2007 (suppl; abstr 3513)
5. Yao JC: Neuroendocrine tumors: Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 21:163-172, 2007
6. Motzer RJ, Escudier BJ, Ouard S, et al: RAD001 plus best supportive care (BSC) versus BSC plus placebo in patients with metastatic renal cell carcinoma (RCC) that has progressed on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase III study. J Clin Oncol 26:256s, 2008 (suppl; abstr LBA5026)
7. Kurokawa H, Lenferink AE, Simpson JF, et al: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER-2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60:5887-5894, 2000
8. Kurokawa H, Arteaga CL: ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 9:511S-515S, 2003
9. Stoica GE, Franke TF, Wellstein A, et al: Heregulin-beta1 regulates the estrogen receptor-α gene expression and activity via the ErbB2/PI 3-K/ Akt pathway. Oncogene 22:2073-2087, 2003
10. Stoica GE, Franke TF, Wellstein A, et al: Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 17:818-830, 2003
11. Perez-Tenorio G, Stal O: Activation of AKT/ PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545, 2002
12. Stal O, Perez-Tenorio G, Akerberg L, et al: Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5:R37-R44, 2003
13. Tokunaga E, Kataoka A, Kimura Y, et al: The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 42:629-635, 2006
14. deGraffenried LA, Friedrichs WE, Russell DH, et al: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 10:8059-8067, 2004
15. Beeram M, Tan QT, Tekmal RR, et al: Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 18:1323-1328, 2007
16. Behrens D, Lykkesfeldt AE, Fichtner I: The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts. Targeted Oncol 2:135-144, 2007
17. Boulay A, Rudloff J, Ye J, et al: Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11:5319-5328, 2005
18. Awada A, Cardoso F, Fontaine C, et al: The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer 44:84-91, 2008
19. Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170, 2007
20. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001
21. Dixon JM, Renshaw L, Bellamy C, et al: The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study. Clin Cancer Res 6:2229-2235, 2000
22. Shoma A, Moutamed A, Ameen M, et al: Ultrasound for accurate measurement of invasive breast cancer tumor size. Breast J 12:252-256, 2006
23. Guarneri V, Broglio K, Kau SW, et al: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-1044, 2006
24. Locker AP, Birrell K, Bell JA, et al: Ki67 immunoreactivity in breast carcinoma: Relationships to prognostic variables and short term survival. Eur J Surg Oncol 18:224-229, 1992
25. Urruticoechea A, Smith IE, Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212-7220, 2005
26. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359: 2131-2139, 2002
27. Barbareschi M, Buttitta F, Felicioni L, et al: Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13:6064-6069, 2007
28. O'Donnell A, Faivre S, Burris HA III, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588-1595, 2008
29. Tabernero J, Rojo F, Calvo E, et al: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610, 2008
30. Chow L, Sun Y, Jassem J, et al: Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 100:S28, 2006 (abstr 6091)